Human TRAIL R3/TNFRSF10C PE-conjugated Antibody

Catalog # Availability Size / Price Qty
FAB6302P
Human TRAIL R3/TNFRSF10C PE-conjugated Antibody in Data
1 Image
Product Details
Citations (12)
FAQs
Supplemental Products
Reviews

Human TRAIL R3/TNFRSF10C PE-conjugated Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R1, or rhTRAIL R4 is observed.
Source
Monoclonal Mouse IgG1 Clone # 90906
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C
Met1-Ala221
Accession # O14798
Formulation
Supplied in a saline solution containing BSA and Sodium Azide.
Label
Phycoerythrin (Excitation= 488 nm, Emission= 565-605 nm)

Applications

Recommended Concentration
Sample
Flow Cytometry
10 µL/106 cells
See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Flow Cytometry Detection of TRAIL R3/TNFRSF10C antibody in Human Blood Granulocytes antibody by Flow Cytometry. View Larger

Detection of TRAIL R3/TNFRSF10C in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human TRAIL R3/TNFRSF10C PE-conjugated Monoclonal Antibody (Catalog # FAB6302P, filled histogram) or isotype control antibody (Catalog # IC002P, open histogram). View our protocol for Staining Membrane-associated Proteins.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.

Background: TRAIL R3/TNFRSF10C

Human TRAIL R3, also known as DcR1 (Decoy Receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References
  1. Sheridan, J.P. et al. (1997) Science 277:818.
  2. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 3
Entrez Gene IDs
8794 (Human)
Alternate Names
Antagonist decoy receptor for TRAIL/Apo-2L; CD263 antigen; CD263; cytotoxic TRAIL receptor-3; DcR1; DCR1MGC149502; Decoy receptor 1; Decoy TRAIL receptor without death domain; LITMGC149501; Lymphocyte inhibitor of TRAIL; TNFRSF10C; TRAIL R3; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAILR3; TRAIL-R3; TRAILR3TNF-related apoptosis-inducing ligand receptor 3; TRIDDCR1-TNFR; tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain

Product Datasheets

Citations for Human TRAIL R3/TNFRSF10C PE-conjugated Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

12 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
    Authors: EB Jo, YS Lee, H Lee, JB Park, H Park, YL Choi, D Hong, SJ Kim
    BMC Cancer, 2019;19(1):496.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  2. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis
    Authors: HD Singh, I Otano, K Rombouts, KP Singh, D Peppa, US Gill, K Böttcher, PTF Kennedy, J Oben, M Pinzani, H Walczak, G Fusai, WMC Rosenberg, MK Maini
    Sci Rep, 2017;7(1):5514.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
    Authors: Y Shlyakhtin, V Pavet, H Gronemeyer
    Cell Death Dis, 2017;8(8):e3025.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells
    Authors: D Jaworska, E Szliszka
    Int J Mol Sci, 2017;18(8):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Authors: Kim, Seong Mu, Woo, Ji Sun, Jeong, Chang Hy, Ryu, Chung He, Jang, Jae-Deog, Jeun, Sin-Soo
    Stem Cells Transl Med, 2014;3(2):172-82.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
    Authors: Gojo I, Tan M, Fang H, Sadowska M, Lapidus R, Baer M, Carrier F, Beumer J, Anyang B, Srivastava R, Espinoza-Delgado I, Ross D
    Clin Cancer Res, 2013;19(7):1838-51.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Flow Cytometry
  8. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity.
    Authors: Kalb ML, Glaser A, Stary G, Koszik F, Stingl G
    J. Immunol., 2012;188(4):1583-91.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Authors: Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS
    Cancer Res., 2008;68(23):9614-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
    Stem Cells, 2008;26(11):2955-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
    Authors: Wu CH, Kao CH, Safa AR
    Hum. Gene Ther., 2008;19(7):731-43.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
    Authors: Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK
    J. Exp. Med., 2007;204(3):667-80.
    Species: Human
    Sample Types: Serum
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Reviews for Human TRAIL R3/TNFRSF10C PE-conjugated Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL R3/TNFRSF10C PE-conjugated Antibody and earn rewards!

Have you used Human TRAIL R3/TNFRSF10C PE-conjugated Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review